These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38511407)

  • 21. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.
    Cui X; Snapper CM
    Front Immunol; 2021; 12():734471. PubMed ID: 34691042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The association of Epstein-Barr virus infection with CXCR3
    van Langelaar J; Wierenga-Wolf AF; Samijn JPA; Luijks CJM; Siepman TA; van Doorn PA; Bell A; van Zelm MC; Smolders J; van Luijn MM
    Eur J Immunol; 2021 Mar; 51(3):626-633. PubMed ID: 33152118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epstein-Barr virus and multiple sclerosis.
    Lünemann JD; Münz C
    Curr Neurol Neurosci Rep; 2007 May; 7(3):253-8. PubMed ID: 17488592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diversification and expansion of the EBV-reactive cytotoxic T lymphocyte repertoire following autologous haematopoietic stem cell transplant for multiple sclerosis.
    Massey J; Artuz C; Dyer Z; Jackson K; Khoo M; Visweswaran M; Withers B; Moore J; Ma D; Sutton I
    Clin Immunol; 2023 Sep; 254():109709. PubMed ID: 37495004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MINI-review of Epstein-Barr virus involvement in multiple sclerosis etiology and pathogenesis.
    Aloisi F; Cross AH
    J Neuroimmunol; 2022 Oct; 371():577935. PubMed ID: 35931008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Attenuated immune control of Epstein-Barr virus in humanized mice is associated with the multiple sclerosis risk factor HLA-DR15.
    Zdimerova H; Murer A; Engelmann C; Raykova A; Deng Y; Gujer C; Rühl J; McHugh D; Caduff N; Naghavian R; Pezzino G; Capaul R; Zbinden A; Ferlazzo G; Lünemann JD; Martin R; Chatterjee B; Münz C
    Eur J Immunol; 2021 Jan; 51(1):64-75. PubMed ID: 32949466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epstein-Barr virus cause of multiple sclerosis.
    Tselis A
    Curr Opin Rheumatol; 2012 Jul; 24(4):424-8. PubMed ID: 22617821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Altered EBV specific immune control in multiple sclerosis.
    Münz C
    J Neuroimmunol; 2024 May; 390():578343. PubMed ID: 38615370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epstein-Barr virus and multiple sclerosis.
    Pohl D
    J Neurol Sci; 2009 Nov; 286(1-2):62-4. PubMed ID: 19361810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
    Niller HH; Wolf H; Minarovits J
    Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Altered Immune Response to the Epstein-Barr Virus as a Prerequisite for Multiple Sclerosis.
    Läderach F; Münz C
    Cells; 2022 Sep; 11(17):. PubMed ID: 36078165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ineffective control of Epstein-Barr-virus-induced autoimmunity increases the risk for multiple sclerosis.
    Vietzen H; Berger SM; Kühner LM; Furlano PL; Bsteh G; Berger T; Rommer P; Puchhammer-Stöckl E
    Cell; 2023 Dec; 186(26):5705-5718.e13. PubMed ID: 38091993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EBV-related lymphomas: new approaches to treatment.
    Kanakry JA; Ambinder RF
    Curr Treat Options Oncol; 2013 Jun; 14(2):224-36. PubMed ID: 23549980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gender and the Sex Hormone Estradiol Affect Multiple Sclerosis Risk Gene Expression in Epstein-Barr Virus-Infected B Cells.
    Keane JT; Afrasiabi A; Schibeci SD; Fewings N; Parnell GP; Swaminathan S; Booth DR
    Front Immunol; 2021; 12():732694. PubMed ID: 34566997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EBNA1 Inhibitors Block Proliferation of Spontaneous Lymphoblastoid Cell Lines From Patients With Multiple Sclerosis and Healthy Controls.
    Monaco MCG; Soldan SS; Su C; Clauze A; Cooper JF; Patel RJ; Lu F; Hughes RJ; Messick TE; Andrada FC; Ohayon J; Lieberman PM; Jacobson S
    Neurol Neuroimmunol Neuroinflamm; 2023 Sep; 10(5):. PubMed ID: 37562974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epstein-Barr virus and multiple sclerosis: Updating Pender's hypothesis.
    Laurence M; Benito-León J
    Mult Scler Relat Disord; 2017 Aug; 16():8-14. PubMed ID: 28755684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary Peripheral Epstein-Barr Virus Infection Can Lead to CNS Infection and Neuroinflammation in a Rabbit Model: Implications for Multiple Sclerosis Pathogenesis.
    Hassani A; Reguraman N; Shehab S; Khan G
    Front Immunol; 2021; 12():764937. PubMed ID: 34899715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy.
    Aloisi F; Giovannoni G; Salvetti M
    Lancet Neurol; 2023 Apr; 22(4):338-349. PubMed ID: 36764322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of innate immune activation with latent Epstein-Barr virus in active MS lesions.
    Tzartos JS; Khan G; Vossenkamper A; Cruz-Sadaba M; Lonardi S; Sefia E; Meager A; Elia A; Middeldorp JM; Clemens M; Farrell PJ; Giovannoni G; Meier UC
    Neurology; 2012 Jan; 78(1):15-23. PubMed ID: 22156987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
    Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
    Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.